2025
Moderating effect of insulin resistance on the relationship between cortical surface area and cognitive function in patients with first-episode schizophrenia
Lin C, Gou M, Pan S, Tong J, Zhou Y, Xie T, Yu T, Li Y, Cui Y, Tian B, Tan S, Wang Z, Luo X, Zhang P, Huang J, Chen S, Yin Y, Tan Y. Moderating effect of insulin resistance on the relationship between cortical surface area and cognitive function in patients with first-episode schizophrenia. Psychiatry Research Neuroimaging 2025, 352: 112048. PMID: 40829289, DOI: 10.1016/j.pscychresns.2025.112048.Peer-Reviewed Original ResearchConceptsCortical surface areaMCCB composite scoreFirst-episode schizophreniaCognitive functionCognitive deficitsPositive and Negative Symptom ScaleSchizophrenia Consensus Cognitive BatteryCognitive impairmentLeft middle temporal gyrusCaudal anterior cingulate gyrusConsensus Cognitive BatteryNegative Symptom ScaleComposite scoreMiddle temporal gyrusAnterior cingulate gyrusMechanism of cognitive impairmentModerating effectMCCB domainsCognitive batteryVerbal learningTemporal gyrusTreatment researchCingulate gyrusSchizophreniaBrain structures
2024
Targeted metabolomics-based understanding of the sleep disturbances in drug-naïve patients with schizophrenia
Yan H, Li G, Zhang X, Zhang C, Li M, Qiu Y, Sun W, Dong Y, Li S, Li J. Targeted metabolomics-based understanding of the sleep disturbances in drug-naïve patients with schizophrenia. BMC Psychiatry 2024, 24: 355. PMID: 38741058, PMCID: PMC11089724, DOI: 10.1186/s12888-024-05805-0.Peer-Reviewed Original ResearchConceptsPositive and Negative Symptom ScaleDrug-naive patientsLiquid chromatography-mass spectrometryDrug-naive schizophreniaAssociated with sleep disturbancesOrthogonal partial least squares discriminant analysisSleep disturbancePittsburgh Sleep Quality IndexPartial least-squares discriminant analysisMetabolomics-based approachNegative Symptom ScaleChromatography-mass spectrometryCharacteristic metabolitesSchizophreniaSymptom ScaleMethodsPlasma samplesPotential biological mechanismsSleep Quality IndexClinical symptomsGlycerophospholipid metabolismPartial correlation analysisHealthy controlsMetabolomic analysisPatientsBackgroundSleep disturbanceSelective disrupted gray matter volume covariance of amygdala subregions in schizophrenia
Chang Z, Liu L, Lin L, Wang G, Zhang C, Tian H, Liu W, Wang L, Zhang B, Ren J, Zhang Y, Xie Y, Du X, Wei X, Wei L, Luo Y, Dong H, Li X, Zhao Z, Liang M, Zhang C, Wang X, Yu C, Qin W, Liu H. Selective disrupted gray matter volume covariance of amygdala subregions in schizophrenia. Frontiers In Psychiatry 2024, 15: 1349989. PMID: 38742128, PMCID: PMC11090100, DOI: 10.3389/fpsyt.2024.1349989.Peer-Reviewed Original ResearchGray matter volume covarianceGray matter volumeAnterior amygdaloid areaAmygdala subregionsSchizophrenia patientsNegative Symptom ScaleVoxel-wise general linear modelHealthy controlsDuration of illnessOrbitofrontal cortexMatter volumeRight BASchizophreniaAmygdalaSymptom ScaleConnectivity patternsSubregionsSample size of patientsSize of patientsFunctional abnormalitiesCorrelation analysisStriatumGeneralized linear modelPatientsHippocampus
2023
Associations between metabolic disorders and sleep disturbance in patients with schizophrenia
Yan H, Huang Z, Lu Y, Qiu Y, Li M, Li J. Associations between metabolic disorders and sleep disturbance in patients with schizophrenia. Comprehensive Psychiatry 2023, 122: 152369. PMID: 36702060, DOI: 10.1016/j.comppsych.2023.152369.Peer-Reviewed Original ResearchConceptsPositive and Negative Symptom ScaleSubjective sleep qualitySleep disturbanceSleep latencyPittsburgh Sleep Quality IndexSleep qualityNegative Symptom ScaleDuration of illnessLonger sleep latencySchizophrenia patientsDrug-naiveRate of MDSchizophreniaAssociated with MDSymptom ScaleMental illnessSleep Quality IndexTotal scorePartial correlation analysisImprove sleep qualityMetabolic disordersDevelopment of MDPredictors of MDBody mass indexClinical correlates
2022
Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness
Lin C, Gou M, Pan S, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Luo X, Li CR, Zhang P, Huang J, Hong L, Tan Y. Serum hyperhomocysteine and cognitive impairment in first-episode patients with schizophrenia: Moderated by brain cortical thickness. Neuroscience Letters 2022, 788: 136826. PMID: 35944595, DOI: 10.1016/j.neulet.2022.136826.Peer-Reviewed Original ResearchConceptsBrain cortical thicknessCognitive impairmentCognitive deficitsGray matter thicknessSchizophrenia (MATRICS) Consensus Cognitive BatteryAttention/vigilanceConsensus Cognitive BatteryCortical thicknessSerum Hcy levelsFirst-episode patientsHealthy controlsHigh homocysteineWorking memoryHcy levelsCognitive batteryNegative Symptom ScaleCognitive functionTreatment researchHigh-resolution magnetic resonance imagingSymptom ScaleSandwich enzyme-linked immunosorbentSchizophreniaHigher cortical thicknessImpairmentEnzyme-linked immunosorbent
2020
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia. New England Journal Of Medicine 2020, 382: 1497-1506. PMID: 32294346, DOI: 10.1056/nejmoa1911772.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdultAntipsychotic AgentsDouble-Blind MethodDrug Administration ScheduleFemaleHumansLeast-Squares AnalysisMaleReceptors, Dopamine D2Receptors, G-Protein-CoupledSchizophreniaSchizophrenic PsychologySerotonin 5-HT1 Receptor AgonistsSeverity of Illness IndexTreatment OutcomeConceptsTrace amine-associated receptor 1Week 4Negative Symptom ScaleAcute exacerbationPlacebo groupBrief Negative Symptom ScaleTotal scoreSymptom ScaleClinical Global Impression-Severity ScaleEnd pointPrimary end pointSecondary end pointsSudden cardiac deathPANSS total scoreTreatment of schizophreniaDopamine D2 receptorsTreatment of psychosisType 1A receptorMean total scoreLevels of lipidsGastrointestinal symptomsAdverse eventsCardiac deathExtrapyramidal symptomsPrimary outcome
2018
F249. FAMILY BURDEN IN THE US RAISE-ETP PROGRAM: TREATMENT EFFECTS AND PREDICTORS
Glynn S, Gingerich S, Meyer-Kalos P, Mueser K, Chan-Golston A, Sugar C, Schooler N, Rosenheck R, Kane J. F249. FAMILY BURDEN IN THE US RAISE-ETP PROGRAM: TREATMENT EFFECTS AND PREDICTORS. Schizophrenia Bulletin 2018, 44: s320-s320. PMCID: PMC5888551, DOI: 10.1093/schbul/sby017.780.Peer-Reviewed Original ResearchBurden Assessment ScaleFirst-episode psychosisFamily burdenCustomary careInitial Schizophrenia Episode Early Treatment ProgramTreatment programTotal scoreEarly Treatment ProgramIndividual resiliency trainingSignificant independent predictorsSpecialty care programNon-affective psychosisDSM-IV diagnosisEpisode of psychosisHeinrichs-Carpenter QualityNegative Symptom ScaleSpecific program componentsPsychotic medicationIndependent predictorsClinical history informationCSC programsFunctional improvementEpisode psychosisTotal QOLStudy participation
2012
Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study
Zhang X, Chen D, Xiu M, Haile C, He S, Luo X, Zuo L, Rosenheck R, Kosten T, Kosten T. Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study. Psychological Medicine 2012, 43: 1651-1660. PMID: 23149169, DOI: 10.1017/s0033291712002590.Peer-Reviewed Original ResearchConceptsDrug-naive patientsFES patientsGeneral populationCognitive functionChronic schizophreniaHealthy controlsSmoking ratesFirst-episode drug-naive patientsFirst-episode schizophrenia patientsQuantity of smokingPositive symptom subscale scoresCase-control studyHigh smoking ratesSymptom subscale scoresCase-control designNegative Symptom ScaleTotal PANSSCigarette smokingFirst episodeNicotine dependenceFagerström TestPatientsPsychotic disordersSmokingSymptom Scale
2003
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2003, 172: 291-297. PMID: 14634716, DOI: 10.1007/s00213-003-1658-9.Peer-Reviewed Original ResearchConceptsFederal Drug AdministrationSide effectsDrinking daysAlcohol dependenceDouble-blind fashionEfficacy of naltrexoneAbnormal involuntary movementsComorbid alcohol dependenceHeavy drinking daysTreatment of alcoholismSymptoms of schizophreniaRelapse prevention strategiesNegative Symptom ScaleNaltrexone augmentationTime-line follow-back methodNeuroleptic medicationNeuroleptic treatmentEffective medicationsMedication complianceComorbid schizophreniaOutpatient studyWeekly therapyEffective pharmacotherapyConclusionsThese dataInvoluntary movements
2000
Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans
Fujita M, Verhoeff N, Varrone A, Zoghbi S, Baldwin R, Jatlow P, Anderson G, Seibyl J, Innis R. Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans. European Journal Of Pharmacology 2000, 387: 179-188. PMID: 10650158, DOI: 10.1016/s0014-2999(99)00817-1.Peer-Reviewed Original ResearchConceptsAcute dopamine depletionDopamine depletionEndogenous dopamineAlpha-methylTemporal cortexExtrastriatal dopamine D2 receptor occupancyDopamine D2 receptor occupancyD2 receptor occupancySynaptic dopamine concentrationsSingle photon emissionNegative Symptom ScalePara-tyrosineExtrastriatal regionsOral administrationHealthy humansSymptom ScaleReceptor occupancyDopamine concentrationsDysphoric moodDopaminePhoton emissionHigh-affinity ligandsCortexVivo measurementsThalamus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply